Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Lijie Xing, MD, Liang Lin, PhD, Tengteng Yu, MD PhD, Yuyin Li, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1817.

https://doi.org/10.1182/blood-2019-127163

Published: 2019

Journal Articles

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Lijie Xing, MD, Yuyin Li, PhD, Liang Lin, PhD, Tengteng Yu, MD PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3096.

https://doi.org/10.1182/blood-2019-127135

Published: 2019

Journal Articles

Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers

Nabendu Pore, Kevin P Schifferli, Noel R Monks, Ravinder Tammali, Martin Borrok, Elaine Hurt, Matt Flynn, Marlon Rebelatto, Danielle M. Townsley, MD MSc, Mary Jane Hinrichs, Rakesh Dixit, Steven Coats, Ronald Herbst, David Tice

Blood (2018) 132 (Supplement 1): 4071.

https://doi.org/10.1182/blood-2018-99-119836

Published: 2018

Journal Articles

CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics

Katherine Tarlock, MD, Zixing Wang, Rory Rohm, Travis Biechele, Rhonda E. Ries, MA, Tiffany Hylkema, BS, Jatinder K Lamba, PhD, Gary D Means, PhD, Robert Thurman, Bill Arthur, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 3942.

https://doi.org/10.1182/blood-2018-99-113932

Published: 2018

Journal Articles

Beta3-Adrenergic Blockade Restores Erythropoietic Homeostasis in Anemia of Critical Illness

Kuzhali Muthumalaiappan, PhD, Shirin Hasan, PhD, Ameet Kini, MD PhD, Pravesh Saini, BS, Julia Walczak, Anthony J Baldea, MD

Blood (2018) 132 (Supplement 1): 3615.

https://doi.org/10.1182/blood-2018-99-112194

Published: 2018

Journal Articles

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Marianne T. Santaguida, BSc, PhD, Christos Gekas, PhD, Todd A Alonzo, PhD, Robert B Gerbing, MA, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Tiffany Hylkema, BS, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Hamid Bolouri, PhD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 881.

https://doi.org/10.1182/blood-2018-99-115544

Published: 2018

Journal Articles

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, MD, Graham P. Collins, MB BS DPhil, Felipe Samaniego, MD, Alexander I Spira, MD, Andrew Davies, John Radford, MD FRCP, Paolo Caimi, MD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 928.

https://doi.org/10.1182/blood-2018-99-118198

Published: 2018

Journal Articles

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali S. Advani, Daniel J. DeAngelo, Tibor J. Kovacsovics, Anand Jillella, Dale Bixby, Moshe Y. Levy, Megan M. O’Meara, Phoenix A. Ho, Jenna Voellinger, Anthony S. Stein

Blood (2018) 132 (11): 1125–1133.

https://doi.org/10.1182/blood-2018-03-841171

Published: 2018

Journal Articles

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter C. Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E. G. Havenith, Simon Chivers, Francois D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley, Patrick H. van Berkel

Blood (2018) 131 (10): 1094–1105.

https://doi.org/10.1182/blood-2017-10-813493

Published: 2018

Includes: Supplemental data

Journal Articles

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Aaron D Goldberg, MD, Martin S. Tallman, MD, Melhem M Solh, MD, David Ungar, MD, David A. Rizzieri, MD, Roland B. Walter, MD PhD, Alexander I Spira, MD, Ki-Young Chung, MD, Wendy Stock, MD, Shui He, PhD, Joseph Boni, PhD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2662.

https://doi.org/10.1182/blood.V130.Suppl_1.2662.2662

Published: 2017

Journal Articles

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

Morgane Cheminant, MD, Julie Bruneau, MD PhD, Georgia Malamut, MD PhD, David Sibon, Nicolas Guegan, Sascha Cording, PhD, Amélie Trinquand, MD PhD, Nicole Brousse, MD PhD, Sherine Khater, MD, Elizabeth A. Macintyre, PhD FRCP, FRCPath, Vahid Asnafi, MD PhD, Laurent Pouyet, PhD, Florence Lhospice, PharmD, Thierry Jo Molina, MDPhD, Bertrand Meresse, PhD, Christophe Cellier, MD PhD, Nadine Cerf-Bensussan, MD PhD, Olivier Hermine, MD PhD

Blood (2017) 130 (Supplement 1): 2820.

https://doi.org/10.1182/blood.V130.Suppl_1.2820.2820

Published: 2017

Journal Articles

CD25 Enables Oncogenic BCR-Signaling and Represents a Therapeutic Target in B Cell Malignancies

Jaewoong Lee, PhD, Huimin Geng, PhD, Zhengshan Chen, MDPhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Francesca Zammarchi, PhD, Patrick Van Berkel, PhD, Ari Melnick, MD, Elisabeth Paietta, PhD, Markus Muschen, MDPhD

Blood (2017) 130 (Supplement 1): 3834.

https://doi.org/10.1182/blood.V130.Suppl_1.3834.3834

Published: 2017

Journal Articles

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Carmelo Carlo-Stella, MD, Erin Reid, MD, Jay Feingold, MD PhD, Kirit M Ardeshna, MD, John Radford, MD, Melhem M Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, Shui He, PhD, Joseph Boni, PhD, Owen Anthony O'Connor, MD

Blood (2017) 130 (Supplement 1): 187.

https://doi.org/10.1182/blood.V130.Suppl_1.187.187

Published: 2017

Journal Articles

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, Rebecca B. Klisovic, MD, Wendy Stock, MD, David Ungar, MD, Amer M. Zeidan, MD, Ehab Atallah, MD, James McCloskey, MD, Leonard Heffner, MD, Benjamin Tomlinson, MD, Hagop M. Kantarjian, MD, Shui He, PhD, Joseph Boni, PhD, Matthew J. Wieduwilt

Blood (2017) 130 (Supplement 1): 1321.

https://doi.org/10.1182/blood.V130.Suppl_1.1321.1321

Published: 2017

Journal Articles

Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Owen Anthony O'Connor, MD, Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Erin Reid, MD, Jay Feingold, MD PhD, Karin Havenith, PhD, Shui He, PhD, Diane R Mould, PhD, Immanuel Freedman, PhD, Joseph Boni, PhD

Blood (2017) 130 (Supplement 1): 2543.

https://doi.org/10.1182/blood.V130.Suppl_1.2543.2543

Published: 2017

Journal Articles

Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma

Krista Kinneer, John Meekin, Reena Varkey, Xiaodong Xiao, Haihong Zhong, Shannon Breen, Elaine Hurt, Suneetha Thomas, Matt Flynn, Paul Hynes, Binyam Bezabeh, Cui (Tracy) Chen, Leslie Wetzel, Ruoyan Chen, Yu-Tzu Tai, PhD, Kenneth C Anderson, MD, Ronald Herbst, David Tice

Blood (2017) 130 (Supplement 1): 3153.

https://doi.org/10.1182/blood.V130.Suppl_1.3153.3153

Published: 2017

Journal Articles

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies

Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps, Dennis Benjamin

Blood (2017) 130 (18): 2018–2026.

https://doi.org/10.1182/blood-2017-04-779389

Published: 2017

Includes: Supplemental data

Journal Articles

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Jay Yang, MD, Farhad Ravandi, MD, Anjali Advani, MD, Sumithira Vasu, MBBS, Roland B. Walter, MD PhD, Stefan Faderl, MD, Anthony S. Stein, MD, Harry P. Erba, MD PhD, Amir T. Fathi, MD, William B. Donnellan, MD, Moshe Y Levy, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Michael B. Maris, MD

Blood (2016) 128 (22): 340.

https://doi.org/10.1182/blood.V128.22.340.340

Published: 2016

Journal Articles

A PDZ-Binding Motif in DCAF7 Maintains Hematopoietic Homeostasis and Prevents Malignancy in DS-AMKL

Gina Kirsammer, PhD, Rachael F Schultz, BA, Ritika Rastogi, BA, Sandeep Gurbuxani, MBBS, PhD, John Crispino, PhD

Blood (2016) 128 (22): 1205.

https://doi.org/10.1182/blood.V128.22.1205.1205

Published: 2016

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

NARROW

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers

CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics

Beta3-Adrenergic Blockade Restores Erythropoietic Homeostasis in Anemia of Critical Illness

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

CD25 Enables Oncogenic BCR-Signaling and Represents a Therapeutic Target in B Cell Malignancies

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

A PDZ-Binding Motif in DCAF7 Maintains Hematopoietic Homeostasis and Prevents Malignancy in DS-AMKL

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only